SNHG6 and metabolic dysfunction-associated steatotic liver disease: SNHG6 is significantly upregulated in hepatoma compared to normal liver tissue and has been shown to be a cholesterol effector that accelerates progression from non-alcoholic fatty liver disease (NAFLD) to hepatocellular carcinoma (HCC).